SANN Santhera Pharmaceuticals Holding AG

16.19USD13.64 CHF · SWX-1.16%Mkt Cap: 247.95M USDP/E: —

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Euro…

Institutional holders1 on file

Key Statistics

Company
Market Cap247.95M USD
Enterprise Value242.26M USD
Revenue (TTM)120.45M USD
Gross Profit18.01M USD
Net Income (TTM)-58.42M USD
Revenue/Share8.74 USD
Last Price16.19 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees93
CountryCH
SectorHealthcare
IndustryBiotechnology
ISINCH1276028821
Valuation
P/E (Trailing)—
P/E (Forward)62.00
PEG—
EV/EBITDA-56.13
EV/Revenue2.01
P/S2.06
P/B-33.19
EPS (TTM)-2.74 USD
EPS (Forward)0.26 USD
52W Range
12.0140% of range22.36
52W High22.36 USD
52W Low12.01 USD
Profitability
Gross Margin19.66%
Oper. Margin-8.60%
EBITDA Margin-3.58%
Profit Margin-63.79%
ROE416.69%
ROA-33.25%
ROIC-255.99%
ROCE-43.78%
Growth
Revenue Growth101.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-41.25M USD
CapEx (TTM)61.70K USD
FCF Margin-20.85%
FCF Yield-10.13%
Net Debt-586.19K USD
Net Debt/EBITDA0.14
Net Debt/FCF—
Balance Sheet
Debt/Equity-4.14
Current Ratio1.73
Quick Ratio1.10
Book Value/Sh-0.49 USD
Cash/Share3.30 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateSep 8, 2022
Splits
Last Split1:10
Split DateJul 3, 2023
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)32.63 USD
Upside (mean)+101.6%
Target Range29.67 USD – 35.60 USD
29.67+101.6% to mean35.60
# Analysts2
Ownership
Shares Out.15.32M
Float12.64M
Insiders11.15%
Institutions16.77%
Technical
SMA 5017.75 (-8.8%)
SMA 20018.62 (-13.1%)
Beta-0.41
S&P 52W Chg12.00%
Avg Vol (30d)64.99K
Avg Vol (10d)52.98K
Technical Indicators
RSI (14)36.6
MACD-0.2172
MACD Signal-0.0838
MACD Hist.-0.1334
BB Upper18.79 USD
BB Middle17.49 USD
BB Lower16.19 USD
BB Width14.88%
ATR (14)0.6701 USD
Vol Ratio (20d)0.60x

About Santhera Pharmaceuticals Holding (SWX: SANN)

›

Santhera Pharmaceuticals Holding (SWX: SANN) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 93 employees.

The shares were at 13.64 CHF on 19 November 2026, up 27.7% over 52 weeks. Its 52-week range is 10.12 CHF to 18.84 CHF: the price is 27.6% below the high and 34.8% above the low.

Its market capitalisation is 208.95M CHF.

Santhera Pharmaceuticals Holding reports return on equity of 416.7%, an operating margin of -8.6% and revenue up 101.3% year over year.

It holds more cash than debt, a net cash position of 494.00K CHF. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 27.50 CHF is 101.6% above the current price.